Cargando…

HER2-Specific Peptide (LTVSPWY) and Antibody (Herceptin) Targeted Core Cross-Linked Micelles for Breast Cancer: A Comparative Study

This study aims to prepare a novel breast cancer-targeted micelle-based nanocarrier, which is stable in circulation, allowing intracellular drug release, and to investigate its cytotoxicity, apoptosis, and cytostatic effects, in vitro. The shell part of the micelle is composed of zwitterionic sulfob...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bayram, Nazende Nur, Ulu, Gizem Tuğçe, Abdulhadi, Nusaibah Abdulsalam, Gürdap, Seda, İşoğlu, İsmail Alper, Baran, Yusuf, İşoğlu, Sevil Dinçer
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10053834/ https://www.ncbi.nlm.nih.gov/pubmed/36986594 http://dx.doi.org/10.3390/pharmaceutics15030733

Ejemplares similares

Actively-targeted LTVSPWY peptide-modified magnetic nanoparticles for tumor imaging
por: Jie, Li-Yong, et al.
Publicado: (2012)

Selective DNA Delivery to Tumor Cells Using an Oligoarginine-LTVSPWY Peptide
por: Gong, Cheng, et al.
Publicado: (2014)

Herceptin-sensitivity of HER2-transgenic mouse mammary tumors
por: Schwall, RH, et al.
Publicado: (2003)

Serological Her2/neu-determination in patients receiving Herceptin(®)
por: Thomas, A, et al.
Publicado: (2001)

Therapeutic Potentials of Inhibition of Jumonji C Domain-containing Demethylases in Acute Myeloid Leukemia
por: Koca, Duygu, et al.
Publicado: (2020)

Update on HER-2 as a target for cancer therapy: Herceptin in the clinical setting
por: Miles, David W
Publicado: (2001)

Effects of body mass index on the outcomes of percutaneous nephrolithotomy
por: Isoglu, Cemal Selcuk, et al.
Publicado: (2017)

Mannose-Binding Lectin 2 Gene Polymorphism during Pandemic: COVID-19 Family
por: Tukek, Tufan, et al.
Publicado: (2022)

Conjugation, characterization and toxicity of lipophosphoglycan-polyacrylic acid conjugate for vaccination against leishmaniasis
por: Topuzogullari, Murat, et al.
Publicado: (2013)

Presence of HER4 associates with increased sensitivity to Herceptin™ in patients with metastatic breast cancer
por: Sassen, Andrea, et al.
Publicado: (2009)

Kinetic Modeling of DUSP Regulation in Herceptin-Resistant HER2-Positive Breast Cancer
por: Buiga, Petronela, et al.
Publicado: (2019)

Reciprocal Regulation of Annexin A2 and EGFR with Her-2 in Her-2 Negative and Herceptin-Resistant Breast Cancer
por: Shetty, Praveenkumar K., et al.
Publicado: (2012)

Recombinant humanised anti-HER2/neu antibody (Herceptin®) induces cellular death of glioblastomas
por: Mineo, J-F, et al.
Publicado: (2004)

Psoriasis Induced by Trastuzumab (Herceptin®)
por: Kim, Dae Hun, et al.
Publicado: (2013)

HER2 Phosphorylation Is Maintained by a PKB Negative Feedback Loop in Response to Anti-HER2 Herceptin in Breast Cancer
por: Gijsen, Merel, et al.
Publicado: (2010)

Correction: Reciprocal Regulation of Annexin A2 and EGFR with Her-2 in Her-2 Negative and Herceptin-Resistant Breast Cancer
por: Shetty, Praveenkumar K., et al.
Publicado: (2012)

Plant-Made Trastuzumab (Herceptin) Inhibits HER2/Neu+ Cell Proliferation and Retards Tumor Growth
por: Komarova, Tatiana V., et al.
Publicado: (2011)

Correction: HER2 Phosphorylation Is Maintained by a PKB Negative Feedback Loop in Response to Anti-HER2 Herceptin in Breast Cancer
por: Gijsen, Merel, et al.
Publicado: (2016)

The role of Herceptin in early breast cancer
por: Subramanian, Ashok, et al.
Publicado: (2008)

Herceptin in clinical use - early 2000
por: Vogel, CL
Publicado: (2000)

Mild hyperthermia influence on Herceptin(®) properties
por: Escoffre, Jean-Michel, et al.
Publicado: (2015)

The Potential Utility of Curcumin in the Treatment of HER-2-Overexpressed Breast Cancer: An In Vitro and In Vivo Comparison Study with Herceptin
por: Lai, Hung-Wen, et al.
Publicado: (2012)

3, 3′-diindolylmethane Enhances the Effectiveness of Herceptin against HER-2/Neu-Expressing Breast Cancer Cells
por: Ahmad, Aamir, et al.
Publicado: (2013)

Active targeting of HER2-positive breast cancer cells by Herceptin-functionalized organically modified silica nanoparticles
por: Shirshahi, Vahid, et al.
Publicado: (2013)

Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
por: Müller, Volkmar, et al.
Publicado: (2018)

Effects of previous unsuccessful extracorporeal shockwave lithotripsy treatment on the performance and outcome of percutaneous nephrolithotomy
por: Türk, Hakan, et al.
Publicado: (2017)

Upregulated HSP27 in human breast cancer cells reduces Herceptin susceptibility by increasing Her2 protein stability
por: Kang, Se Hun, et al.
Publicado: (2008)

Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin™) in HER2-overexpressing breast cancer cells
por: Menendez, Javier A, et al.
Publicado: (2007)

Use of the anti HER-2/neu antibody Herceptin in the treatment of human breast cancer: biological rationale and clinical results
por: Slamon, DJ
Publicado: (2000)

Herceptin® (trastuzumab) in HER2-positive early breast cancer: a systematic review and cumulative network meta-analysis
por: Wilson, Florence R., et al.
Publicado: (2018)

Transgenic models are predictive: the herceptin and flavopiridol experience
por: Schmidt, E
Publicado: (2003)

Herceptin clinical trials: past, present and future
por: Vogel, CL
Publicado: (2001)

Predictive factors for biochemical recurrence in radical prostatectomy patients
por: Turk, Hakan, et al.
Publicado: (2015)

Why do most c-erbB-2/HER-2-positive breast cancer patients fail to respond to Herceptin?
por: Murphy, ML, et al.
Publicado: (2006)

Why do most c-erbB-2/HER-2-positive breast cancer patients fail to respond to Herceptin?
por: Murphy, ML, et al.
Publicado: (2008)

Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas
por: Martin-Castillo, Begoña, et al.
Publicado: (2015)

Herceptin® (trastuzumab) in HER2-positive early breast cancer: protocol for a systematic review and cumulative network meta-analysis
por: Wilson, Florence R., et al.
Publicado: (2017)

Combinatorial experimental protocols for Erbicin-derived immunoagents and Herceptin
por: De Lorenzo, C, et al.
Publicado: (2007)

Radiation Recall Reaction Induced by Adjuvant Trastuzumab (Herceptin)
por: Chung, Caroline, et al.
Publicado: (2009)

Ultrasound-triggered herceptin liposomes for breast cancer therapy
por: Elamir, Amal, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kmh3pti1is7av57kmvklp8qm4d